ISCP 2024 ANNUAL SCIENTIFIC MEETING HIGHLIGHTS

The congress was held jointly with the Brazilian Society of Clinical Medicine – São Paulo Region, with Dr Celso Amodeo as Congress President. Thirty-nine years after the first ISCP International Symposium, presided over by Prof. Henry N. Neufeld in Tel Aviv in 1985, the congress brought together national and international experts to discuss the latest advances in cardiovascular pharmacotherapy.

Over two days, the programme covered coronary disease, heart failure, arrhythmias, dyslipidaemia, hypertension, diabetes, cardio-oncology and drug interactions, as well as the newest pharmacological innovations for each of these conditions.

Watch the Event Highlights

Access the full ISCP 2024 Final Report (PDF)

Key Figures

• 48 speakers

• 50 scientific activities

• 18 hours of content over two days

• 240 professionals attended on site

• 12 sponsoring companies

Organisation & Committees

Main Committee

• ISCP President: Dr Alberto Lorenzatti

• Congress President: Dr Celso Amodeo

• President of the Scientific Committee: Dr Francisco Antonio Helfenstein Fonseca

Scientific Committee

• Dr Francisco Antonio H. Fonseca

• Dr Celso Amodeo

• Dr Wilson Nadruz

• Dr Luciano Drager

International Committee

• Dr Alberto Lorenzatti

• Dr Felipe Martinez

• Dr Juan Carlos Kaski

• Dr Gheorghe-Andrei Dan

• Dr Antoni Martínez-Rubio

• Dr Koji Hasegawa

Participation

A total of 240 professionals attended the congress on site: 231 from Brazil and 9 international delegates from Spain, Australia, Germany, Belarus, Nigeria, Sweden, Japan, Chile and Argentina.

Scientific Programme

The programme opened with two keynote conferences: the Prof. Henry N. Neufeld Opening Conference, delivered by Prof. Otavio Berwanger on innovative and efficient clinical trial models for cardiovascular pharmacological interventions, and “The Era of Direct Oral Anticoagulants: The Importance of Getting the Right Dose”, by Prof. Renato Lopes.

Main topics included:

• Lipid-lowering therapy and inflammation in CVD

• Hypertension, vascular ageing and renal denervation

• Heart failure and cardiomyopathy therapy

• Atrial fibrillation, oral anticoagulants and antithrombotics

• Cardiovascular prevention, obesity and metabolic dysfunction-associated fatty liver disease

• Personalised medicine and the polypill in clinical practice

• Hormones and drugs, vitamins and probiotics, and immunisation in cardiac patients

Faculty

Abrão José Cury, Alberto Lorenzatti, Alvaro Avezum, Alvaro Sosa Liprandi, Andrea Brandão, Antonio Carlos Pallandri Chagas, Antoni Martínez-Rubio, Audes Feitosa, Bruno Geloneze, Celso Amodeo, Dirceu Rodrigues de Almeida, Doreen Tan, Edileide Barros, Edson Stefanini, Egle Costa, Evandro Tinoco, Fabio Fernandes, Felipe Martinez, Felix Ramires, Fernando Bacal, Francisco Fonseca, Gheorghe-Andrei Dan, Henrique Tria Bianco, João Vicente, José Carlos da Costa Zanon, José Francisco Kerr Saraiva, Juan Carlos Kaski, Koji Hasegawa, Luciano Drager, Luis Gowdak, Luiz Bortolotto, Luiz Fernando Tanajura, Maisa Kairalla, Maria Cristina Izar, Mauricio Wajngarten, Nelson Siqueira, Oswaldo Passarelli Jr, Otavio Berwanger, Otavio Rizzi Coelho, Pablo Avanzas, Renato Lopes, Ricardo Pavanello, Rodrigo Alonso, Tasso Lobo, Thomas Kahan, Valério Fucs, Weimar K. Sebba Barroso de Souza and Wilson Nadruz.

Venue

The meeting was held at the Renaissance São Paulo Hotel (Alameda Santos, 2233 – Jardim Paulista), in the heart of São Paulo, with a plenary hall, exhibition area, media desk and VIP room.

Sponsors

The meeting was made possible with the support of 12 companies:

• Brazilian companies: Aché, Biolab, Brace Pharma, Cardios, Eurofarma, Mantecorp Farmasa, Marjan

• Multinational companies: Bayer, Daiichi Sankyo, FQM, GSK, Medtronic